In vivo assembly drug delivery strategy based on ultra-small nanoparticles: Toward high drug permeation and accumulation for CNV treatment

Jingwen Yu; Yiming Wu; Qixuan Dai; Han Wu; Jintao Pan; Yuli  Guo; Ke Yan; Huimin Zhu; Yi Mao; Sijie Lin; Wei Li; Gang Liu; Chengchao Chu

doi:10.1016/j.cej.2022.137968

In vivo assembly drug delivery strategy based on ultra-small nanoparticles: Toward high drug permeation and accumulation for CNV treatment

Jingwen Yu, Yiming Wu, Qixuan Dai, Han Wu, Jintao Pan, Yuli Guo, Ke Yan, Huimin Zhu, Yi Mao, Sijie Lin, Wei Li^*, Gang Liu^*, Chengchao Chu^*

^*Corresponding author for this work

Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Corneal neovascularization (CNV) is one of the common blinding factors worldwide and how to treat CNV effectively is a knotty problem in clinical practice. Although, photothermal therapy (PTT) has been widely investigated in CNV management, it is still limited by the effective delivery of photothermal agents. Hereby, we proposed and validated an in vivo assembly drug delivery strategy, which composed of vascular targeting molecule (RGD-Bis(DPA-Zn), DRUG-1) and ultra-small nanoparticles (AuPt-ICG, DRUG-2). DRUG-2, with PTT and photoacoustic imaging (PAI) properties, could be co-assembled with DRUG-1 to form larger DRUG-1@2 nanocluster, accompanied by performance gains. To treat CNV, DRUG-1 was topically administrated via eye drops; and trapped at the target by the in situ co-assembled with DRUG-1, during which the dual-PAI system was applied to trace drug enrichment; finally, a safe NIR irradiation strategy was implemented to realize efficient CNV elimination. Moreover, the DRUG-1/2 -combined treatment demonstrated better biosecurity and broke new ground for CNV theranostics.

Original language	English
Article number	137968
Number of pages	9
Journal	Chemical Engineering Journal
Volume	450
Early online date	8 Jul 2022
DOIs	https://doi.org/10.1016/j.cej.2022.137968
Publication status	Published - 15 Dec 2022

Bibliographical note

Acknowledgements:
J. Yu, Y. Wu and Q. Dai contributed equally to this work. This work was supported by the National Key R&D Program of China (2018YFA0107301 and 2018YFA0107304), the National Natural Science Foundation of China (NSFC) (81770894, 81470602, 81901876, 81925019, 81801817, and U1705281), the Fundamental Research Funds for the Central Universities (20720190088 and 20720200019), the Program for New Century Excellent Talents in University, China (NCET-13-0502), the Medical and Health Key Project of Xiamen (No. 3502Z20191106), Guangdong Basic and Applied Basic Research Foundation (2114050002159), and the Intramural Research Program, Shenzhen Science and Technology Program (JCYJ20210324121801004), National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health. All animal experiments were approved by the Animal Management and Ethics Committee of Xiamen University.

Keywords

Corneal neovascularization
Photothermal therapy
In vivo assembly
Biosecurity

Access to Document

10.1016/j.cej.2022.137968Licence: None: All rights reserved

Cite this

@article{ee9bc013c61746dc8925c153fda9c847,

title = "In vivo assembly drug delivery strategy based on ultra-small nanoparticles: Toward high drug permeation and accumulation for CNV treatment",

abstract = "Corneal neovascularization (CNV) is one of the common blinding factors worldwide and how to treat CNV effectively is a knotty problem in clinical practice. Although, photothermal therapy (PTT) has been widely investigated in CNV management, it is still limited by the effective delivery of photothermal agents. Hereby, we proposed and validated an in vivo assembly drug delivery strategy, which composed of vascular targeting molecule (RGD-Bis(DPA-Zn), DRUG-1) and ultra-small nanoparticles (AuPt-ICG, DRUG-2). DRUG-2, with PTT and photoacoustic imaging (PAI) properties, could be co-assembled with DRUG-1 to form larger DRUG-1@2 nanocluster, accompanied by performance gains. To treat CNV, DRUG-1 was topically administrated via eye drops; and trapped at the target by the in situ co-assembled with DRUG-1, during which the dual-PAI system was applied to trace drug enrichment; finally, a safe NIR irradiation strategy was implemented to realize efficient CNV elimination. Moreover, the DRUG-1/2 -combined treatment demonstrated better biosecurity and broke new ground for CNV theranostics.",

keywords = "Corneal neovascularization, Photothermal therapy, In vivo assembly, Biosecurity",

author = "Jingwen Yu and Yiming Wu and Qixuan Dai and Han Wu and Jintao Pan and Yuli Guo and Ke Yan and Huimin Zhu and Yi Mao and Sijie Lin and Wei Li and Gang Liu and Chengchao Chu",

note = "Acknowledgements: J. Yu, Y. Wu and Q. Dai contributed equally to this work. This work was supported by the National Key R&D Program of China (2018YFA0107301 and 2018YFA0107304), the National Natural Science Foundation of China (NSFC) (81770894, 81470602, 81901876, 81925019, 81801817, and U1705281), the Fundamental Research Funds for the Central Universities (20720190088 and 20720200019), the Program for New Century Excellent Talents in University, China (NCET-13-0502), the Medical and Health Key Project of Xiamen (No. 3502Z20191106), Guangdong Basic and Applied Basic Research Foundation (2114050002159), and the Intramural Research Program, Shenzhen Science and Technology Program (JCYJ20210324121801004), National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health. All animal experiments were approved by the Animal Management and Ethics Committee of Xiamen University.",

year = "2022",

month = dec,

day = "15",

doi = "10.1016/j.cej.2022.137968",

language = "English",

volume = "450",

journal = "Chemical Engineering Journal",

issn = "1385-8947",

publisher = "Elsevier",

}

TY - JOUR

T1 - In vivo assembly drug delivery strategy based on ultra-small nanoparticles

T2 - Toward high drug permeation and accumulation for CNV treatment

AU - Yu, Jingwen

AU - Wu, Yiming

AU - Dai, Qixuan

AU - Wu, Han

AU - Pan, Jintao

AU - Guo, Yuli

AU - Yan, Ke

AU - Zhu, Huimin

AU - Mao, Yi

AU - Lin, Sijie

AU - Li, Wei

AU - Liu, Gang

AU - Chu, Chengchao

N1 - Acknowledgements: J. Yu, Y. Wu and Q. Dai contributed equally to this work. This work was supported by the National Key R&D Program of China (2018YFA0107301 and 2018YFA0107304), the National Natural Science Foundation of China (NSFC) (81770894, 81470602, 81901876, 81925019, 81801817, and U1705281), the Fundamental Research Funds for the Central Universities (20720190088 and 20720200019), the Program for New Century Excellent Talents in University, China (NCET-13-0502), the Medical and Health Key Project of Xiamen (No. 3502Z20191106), Guangdong Basic and Applied Basic Research Foundation (2114050002159), and the Intramural Research Program, Shenzhen Science and Technology Program (JCYJ20210324121801004), National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health. All animal experiments were approved by the Animal Management and Ethics Committee of Xiamen University.

PY - 2022/12/15

Y1 - 2022/12/15

N2 - Corneal neovascularization (CNV) is one of the common blinding factors worldwide and how to treat CNV effectively is a knotty problem in clinical practice. Although, photothermal therapy (PTT) has been widely investigated in CNV management, it is still limited by the effective delivery of photothermal agents. Hereby, we proposed and validated an in vivo assembly drug delivery strategy, which composed of vascular targeting molecule (RGD-Bis(DPA-Zn), DRUG-1) and ultra-small nanoparticles (AuPt-ICG, DRUG-2). DRUG-2, with PTT and photoacoustic imaging (PAI) properties, could be co-assembled with DRUG-1 to form larger DRUG-1@2 nanocluster, accompanied by performance gains. To treat CNV, DRUG-1 was topically administrated via eye drops; and trapped at the target by the in situ co-assembled with DRUG-1, during which the dual-PAI system was applied to trace drug enrichment; finally, a safe NIR irradiation strategy was implemented to realize efficient CNV elimination. Moreover, the DRUG-1/2 -combined treatment demonstrated better biosecurity and broke new ground for CNV theranostics.

AB - Corneal neovascularization (CNV) is one of the common blinding factors worldwide and how to treat CNV effectively is a knotty problem in clinical practice. Although, photothermal therapy (PTT) has been widely investigated in CNV management, it is still limited by the effective delivery of photothermal agents. Hereby, we proposed and validated an in vivo assembly drug delivery strategy, which composed of vascular targeting molecule (RGD-Bis(DPA-Zn), DRUG-1) and ultra-small nanoparticles (AuPt-ICG, DRUG-2). DRUG-2, with PTT and photoacoustic imaging (PAI) properties, could be co-assembled with DRUG-1 to form larger DRUG-1@2 nanocluster, accompanied by performance gains. To treat CNV, DRUG-1 was topically administrated via eye drops; and trapped at the target by the in situ co-assembled with DRUG-1, during which the dual-PAI system was applied to trace drug enrichment; finally, a safe NIR irradiation strategy was implemented to realize efficient CNV elimination. Moreover, the DRUG-1/2 -combined treatment demonstrated better biosecurity and broke new ground for CNV theranostics.

KW - Corneal neovascularization

KW - Photothermal therapy

KW - In vivo assembly

KW - Biosecurity

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85133943504&partnerID=MN8TOARS

U2 - 10.1016/j.cej.2022.137968

DO - 10.1016/j.cej.2022.137968

M3 - Article

SN - 1385-8947

VL - 450

JO - Chemical Engineering Journal

JF - Chemical Engineering Journal

M1 - 137968

ER -

In vivo assembly drug delivery strategy based on ultra-small nanoparticles: Toward high drug permeation and accumulation for CNV treatment

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this